In Almaty under the chairmanship of the Chairman of the SK-Pharmacy Board Alibaev N.N. have conducted business meeting of the Partnerships with foreign producers of medicines - Octapharma AG Swiss Pharmaceutical Company. This Company creates effective and safe products for hematology, immunology and intensive therapy, has a wide geographic footprint - 39 official representative offices or subsidiaries around the world, as well as 54 donor centers, of which 35 are located in the United States and 9 in Germany. The Company’s medicines are used in more than 80 countries.           

As one of the strategic directions of SK-Pharmacy Company’s development is to establish relationships directly with foreign producers of medicines without analog, this meeting was one of the steps for such cooperation. Since the foundation the Company's weak point was the fact that, to date, the Company had and has no the ability to procure medicines directly from manufacturers, as such it is possible to procure only those manufacturers whose products have no analogs. In other cases, the Company is forced to work with distributors. In recent years there has been systematic work to increase procurement of medicines and medical products under single source contracts with factories-manufacturers. Thus, increased proportion of procurement both among local and foreign manufacturers, and one of the priorities in the development of the Company is to increase the momentum that will inevitably lead to a reduction in purchase prices.

-Unified Distribution System created to improve the sustainability and competitiveness of the pharmaceutical industry by consolidating procurement of medicines. The subject of our interest is the reduction of procurement prices because unlike commercial distributors, SK-Pharmacy has the strategic direction (save budgetary funds allocated from the State budget of Kazakhstan to procure medicines in the context of the guaranteed volume of free medical care. Considerable saving is achieved when the Single distributor buys the medicines, directly from the manufacturer. The dealer is excluded from procurement chain. Also taking into account the duration of the concluded single source contracts to supply of products without analogs, and exclusion from the chain of dealers - commercial distributors, we expect adequate prices from the manufacturer-says the President of SK-Pharmacy Board Mr.Alibaev N.